Switch to:
Also traded in: Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.03
SHPG's Cash to Debt is ranked lower than
98% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 41.89 vs. SHPG: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
SHPG' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.32 Max: No Debt
Current: 0.03
Equity to Asset 0.43
SHPG's Equity to Asset is ranked lower than
76% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SHPG: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
SHPG' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.58 Max: 0.85
Current: 0.43
0.25
0.85
Interest Coverage 1.57
SHPG's Interest Coverage is ranked lower than
97% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 1.57 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s Interest Coverage Range Over the Past 10 Years
Min: 1.57  Med: 27.36 Max: 55.13
Current: 1.57
1.57
55.13
F-Score: 5
Z-Score: 1.07
M-Score: -1.62
WACC vs ROIC
10.10%
3.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 5.67
SHPG's Operating margin (%) is ranked higher than
75% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. SHPG: 5.67 )
Ranked among companies with meaningful Operating margin (%) only.
SHPG' s Operating margin (%) Range Over the Past 10 Years
Min: -56.61  Med: 22.5 Max: 35.13
Current: 5.67
-56.61
35.13
Net-margin (%) 1.09
SHPG's Net-margin (%) is ranked higher than
71% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. SHPG: 1.09 )
Ranked among companies with meaningful Net-margin (%) only.
SHPG' s Net-margin (%) Range Over the Past 10 Years
Min: -59.59  Med: 16.4 Max: 56.55
Current: 1.09
-59.59
56.55
ROE (%) 0.57
SHPG's ROE (%) is ranked higher than
75% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. SHPG: 0.57 )
Ranked among companies with meaningful ROE (%) only.
SHPG' s ROE (%) Range Over the Past 10 Years
Min: -90.17  Med: 17.81 Max: 49.41
Current: 0.57
-90.17
49.41
ROA (%) 0.26
SHPG's ROA (%) is ranked higher than
77% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: -30.04 vs. SHPG: 0.26 )
Ranked among companies with meaningful ROA (%) only.
SHPG' s ROA (%) Range Over the Past 10 Years
Min: -37.5  Med: 9.76 Max: 31.57
Current: 0.26
-37.5
31.57
ROC (Joel Greenblatt) (%) 10.32
SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. SHPG: 10.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -396.76  Med: 110.51 Max: 345.74
Current: 10.32
-396.76
345.74
Revenue Growth (3Y)(%) 15.20
SHPG's Revenue Growth (3Y)(%) is ranked higher than
67% of the 471 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SHPG: 15.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.8  Med: 11.8 Max: 26.7
Current: 15.2
-0.8
26.7
EBITDA Growth (3Y)(%) 18.10
SHPG's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. SHPG: 18.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.9  Med: 20.75 Max: 34.1
Current: 18.1
-1.9
34.1
EPS Growth (3Y)(%) 21.50
SHPG's EPS Growth (3Y)(%) is ranked higher than
77% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. SHPG: 21.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.3  Med: 30.55 Max: 68.8
Current: 21.5
-7.3
68.8
GuruFocus has detected 3 Warning Signs with Shire PLC $SHPG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SHPG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SHPG Guru Trades in Q1 2016

David Dreman 154 sh (New)
Lee Ainslie 1,630 sh (New)
First Eagle Investment 47,032 sh (+873.75%)
Steven Cohen 197,200 sh (+70.29%)
Ken Fisher 39,657 sh (+16.80%)
Jim Simons 313,212 sh (+12.62%)
John Paulson 7,071,050 sh (+3.31%)
Murray Stahl 6,000 sh (unchged)
Pioneer Investments 15,699 sh (unchged)
Paul Tudor Jones 80,000 sh (unchged)
John Paulson 58,000 sh (unchged)
Samuel Isaly 82,128 sh (unchged)
Paul Singer Sold Out
Andreas Halvorsen 130,870 sh (-4.61%)
» More
Q2 2016

SHPG Guru Trades in Q2 2016

Tweedy Browne Global Value 6,803 sh (New)
Jeff Auxier 1,712 sh (New)
Mario Gabelli 5,874 sh (New)
Tweedy Browne 42,247 sh (New)
Third Avenue Management 47,840 sh (New)
Keeley Asset Management Corp 17,723 sh (New)
Jeremy Grantham 28,297 sh (New)
Daniel Loeb 950,000 sh (New)
Mairs and Power 182,790 sh (New)
Leon Cooperman 204,100 sh (New)
John Buckingham 19,575 sh (New)
Julian Robertson 120,554 sh (New)
Paul Singer 39,372 sh (New)
Steve Mandel 2,529,148 sh (New)
Andreas Halvorsen 1,162,787 sh (+788.51%)
Pioneer Investments 35,875 sh (+128.52%)
Murray Stahl 8,068 sh (+34.47%)
First Eagle Investment 56,549 sh (+20.24%)
Lee Ainslie 1,920 sh (+17.79%)
Ken Fisher 44,092 sh (+11.18%)
John Paulson 88,000 sh (unchged)
Samuel Isaly 82,128 sh (unchged)
Jim Simons Sold Out
David Dreman 140 sh (-9.09%)
John Paulson 5,194,600 sh (-26.54%)
Steven Cohen 130,100 sh (-34.03%)
» More
Q3 2016

SHPG Guru Trades in Q3 2016

Lee Ainslie 570,907 sh (+29634.74%)
Ken Fisher 166,168 sh (+276.87%)
Leon Cooperman 356,484 sh (+74.66%)
Steven Cohen 224,900 sh (+72.87%)
Third Avenue Management 68,224 sh (+42.61%)
Tweedy Browne Global Value 6,803 sh (unchged)
Kyle Bass 110,000 sh (unchged)
John Paulson 60,000 sh (unchged)
Jeff Auxier 1,712 sh (unchged)
Samuel Isaly 82,128 sh (unchged)
Jeremy Grantham Sold Out
Paul Singer Sold Out
John Buckingham 19,504 sh (-0.36%)
Keeley Asset Management Corp 17,322 sh (-2.26%)
David Dreman 134 sh (-4.29%)
Daniel Loeb 900,000 sh (-5.26%)
First Eagle Investment 53,037 sh (-6.21%)
Murray Stahl 7,267 sh (-9.93%)
John Paulson 4,667,800 sh (-10.14%)
Tweedy Browne 36,304 sh (-14.07%)
Steve Mandel 1,694,675 sh (-32.99%)
Andreas Halvorsen 764,762 sh (-34.23%)
Mairs and Power 119,577 sh (-34.58%)
Julian Robertson 78,154 sh (-35.17%)
Pioneer Investments 15,699 sh (-56.24%)
Mario Gabelli 1,242 sh (-78.86%)
» More
Q4 2016

SHPG Guru Trades in Q4 2016

Martin Whitman 61,638 sh (+46.28%)
Tweedy Browne Global Value 6,803 sh (unchged)
Ken Fisher 151,274 sh (-8.96%)
Spiros Segalas 2,513,890 sh (-7.02%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:CSLLY, NAS:REGN, NAS:BIIB, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, NAS:BMRN, OTCPK:UCBJY, NAS:GRFS, OTCPK:GMXAY, OTCPK:NVZMY, NAS:CELG, NAS:ALKS, NAS:SGEN, NAS:TSRO, NAS:JAZZ, OTCPK:NONOF, NAS:UTHR, NAS:IONS » details
Traded in other countries:S7E.Germany, SHPG N.Mexico, SHP.UK, SHPGF.USA,
Shire PLC is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs.

Shire PLC is a biotech company incorporated and registered in Jersey on January 28, 2008. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet unmet patient needs. Its Products include FIRAZYR, LDX, NATPAR, SHP609, GATTEX, INTUNIV, TYVENSE, VENVANSE, OBIZUR, HEMOFIL, FOZNOL among others. The Company develops products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a franchise in Oncology.

Top Ranked Articles about Shire PLC

Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4 Fund reveals its picks earlier than most
Third Avenue Management (Trades, Portfolio), a private investment firm founded by legendary value manager Martin Whitman (Trades, Portfolio), ends its quarter on Oct. 31 and revealed the fourth-quarter trades of its Third Avenue Value Fund in its recent letter. Read more...
Steve Mandel Buys Shire, Axes 6 Positions in 2nd Quarter Guru reports quarterly portfolio
Steve Mandel (Trades, Portfolio), founder of Lone Pine Capital, utilizes a long-short equity strategy to create long-term capital growth. During the second quarter, the fund manager bought Shire PLC (NASDAQ:SHPG), reduced three existing positions and eliminated three stakes. Read more...
Leon Cooperman's Omega Buys Netflix, Citigroup, Shire Investor said this year he was finding many undervalued stocks
Leon Cooperman (Trades, Portfolio)’s much-followed firm Omega Advisors added 25 new stocks from a wide variety of industries in the recent quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 138.51
SHPG's P/E(ttm) is ranked lower than
88% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 28.00 vs. SHPG: 138.51 )
Ranked among companies with meaningful P/E(ttm) only.
SHPG' s P/E(ttm) Range Over the Past 10 Years
Min: 12.4  Med: 26.16 Max: 162.3
Current: 138.51
12.4
162.3
Forward P/E 10.04
SHPG's Forward P/E is ranked higher than
85% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. SHPG: 10.04 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 76.43
SHPG's PE(NRI) is ranked lower than
79% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 28.16 vs. SHPG: 76.43 )
Ranked among companies with meaningful PE(NRI) only.
SHPG' s PE(NRI) Range Over the Past 10 Years
Min: 12.87  Med: 23.17 Max: 106.93
Current: 76.43
12.87
106.93
Price/Owner Earnings (ttm) 41.31
SHPG's Price/Owner Earnings (ttm) is ranked lower than
61% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 30.02 vs. SHPG: 41.31 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SHPG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.33  Med: 24.17 Max: 72.9
Current: 41.31
11.33
72.9
P/B 1.76
SHPG's P/B is ranked higher than
76% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. SHPG: 1.76 )
Ranked among companies with meaningful P/B only.
SHPG' s P/B Range Over the Past 10 Years
Min: 1.7  Med: 5.49 Max: 14.19
Current: 1.76
1.7
14.19
P/S 4.74
SHPG's P/S is ranked higher than
71% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 10.85 vs. SHPG: 4.74 )
Ranked among companies with meaningful P/S only.
SHPG' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 4.68 Max: 9.24
Current: 4.74
2.25
9.24
POCF 18.70
SHPG's POCF is ranked higher than
54% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 19.90 vs. SHPG: 18.70 )
Ranked among companies with meaningful POCF only.
SHPG' s POCF Range Over the Past 10 Years
Min: 7.66  Med: 17.09 Max: 27
Current: 18.7
7.66
27
EV-to-EBIT 155.35
SHPG's EV-to-EBIT is ranked lower than
95% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. SHPG: 155.35 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 16.8 Max: 173.7
Current: 155.35
-16.1
173.7
EV-to-EBITDA 29.73
SHPG's EV-to-EBITDA is ranked lower than
68% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 16.65 vs. SHPG: 29.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.6  Med: 13.5 Max: 33.2
Current: 29.73
-19.6
33.2
PEG 3.69
SHPG's PEG is ranked lower than
69% of the 99 Companies
in the Global Biotechnology industry.

( Industry Median: 1.96 vs. SHPG: 3.69 )
Ranked among companies with meaningful PEG only.
SHPG' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 1.1 Max: 4.43
Current: 3.69
0.47
4.43
Shiller P/E 55.42
SHPG's Shiller P/E is ranked lower than
54% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 48.03 vs. SHPG: 55.42 )
Ranked among companies with meaningful Shiller P/E only.
SHPG' s Shiller P/E Range Over the Past 10 Years
Min: 42.92  Med: 101.75 Max: 469
Current: 55.42
42.92
469
Current Ratio 1.25
SHPG's Current Ratio is ranked lower than
84% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. SHPG: 1.25 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.72 Max: 7.43
Current: 1.25
0.52
7.43
Quick Ratio 0.57
SHPG's Quick Ratio is ranked lower than
91% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. SHPG: 0.57 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.51 Max: 7.07
Current: 0.57
0.4
7.07
Days Inventory 299.72
SHPG's Days Inventory is ranked lower than
84% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. SHPG: 299.72 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 190.45 Max: 299.72
Current: 299.72
126.5
299.72
Days Sales Outstanding 109.45
SHPG's Days Sales Outstanding is ranked lower than
75% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 61.83 vs. SHPG: 109.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 67.39 Max: 109.45
Current: 109.45
47.71
109.45

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
SHPG's Dividend Yield is ranked lower than
86% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SHPG: 0.50 )
Ranked among companies with meaningful Dividend Yield only.
SHPG' s Dividend Yield Range Over the Past 10 Years
Min: 0.23  Med: 0.41 Max: 0.7
Current: 0.5
0.23
0.7
Dividend Payout 0.41
SHPG's Dividend Payout is ranked lower than
57% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. SHPG: 0.41 )
Ranked among companies with meaningful Dividend Payout only.
SHPG' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.41
Current: 0.41
0.04
0.41
Dividend Growth (3y) 16.70
SHPG's Dividend Growth (3y) is ranked higher than
72% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. SHPG: 16.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SHPG' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 15.4 Max: 57.8
Current: 16.7
0
57.8
Forward Dividend Yield 0.50
SHPG's Forward Dividend Yield is ranked lower than
87% of the 226 Companies
in the Global Biotechnology industry.

( Industry Median: 1.59 vs. SHPG: 0.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.08
SHPG's Yield on cost (5-Year) is ranked lower than
67% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 1.64 vs. SHPG: 1.08 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPG' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.5  Med: 0.89 Max: 1.52
Current: 1.08
0.5
1.52
3-Year Average Share Buyback Ratio -2.20
SHPG's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. SHPG: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -50.3  Med: -2.1 Max: 0.4
Current: -2.2
-50.3
0.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.83
SHPG's Price/Projected FCF is ranked higher than
67% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.87 vs. SHPG: 1.83 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.15  Med: 1.81 Max: 3.78
Current: 1.83
1.15
3.78
Price/Median PS Value 1.01
SHPG's Price/Median PS Value is ranked lower than
55% of the 593 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. SHPG: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 0.96 Max: 2.68
Current: 1.01
0.52
2.68
Price/Peter Lynch Fair Value 3.77
SHPG's Price/Peter Lynch Fair Value is ranked lower than
73% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 1.63 vs. SHPG: 3.77 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.54  Med: 1.27 Max: 4.25
Current: 3.77
0.54
4.25
Earnings Yield (Greenblatt) (%) 0.60
SHPG's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. SHPG: 0.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 5.5 Max: 8.4
Current: 0.6
0.6
8.4
Forward Rate of Return (Yacktman) (%) 21.13
SHPG's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.27 vs. SHPG: 21.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 2.4 Max: 28.9
Current: 21.13
1.5
28.9

More Statistics

Revenue (TTM) (Mil) $9,306
EPS (TTM) $ 1.55
Beta1.59
Short Percentage of Float0.27%
52-Week Range $147.60 - 209.22
Shares Outstanding (Mil)301.40

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 9,582 12,676 17,468 19,570
EPS ($) 13.42 16.08 19.43 24.44
EPS w/o NRI ($) 13.42 16.08 19.43 24.44
EPS Growth Rate
(3Y to 5Y Estimate)
12.71%
Dividends Per Share ($) 0.91 1.24 1.82
» More Articles for SHPG

Headlines

Articles On GuruFocus.com
Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4 Dec 23 2016 
Julian Robertson Sells Delta Air Lines, Alphabet Dec 07 2016 
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016 
Martin Whitman's Top Recent Investments Oct 12 2016 
John Paulson’s Health Care Picks Plunge in Flat Year for Sector Oct 06 2016 
Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter Sep 27 2016 
Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
Third Avenue Value Fund 3rd Quarter Letter Sep 14 2016 

More From Other Websites
Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA Jan 20 2017
Is Shire plc a Great Stock for Value Investors? Jan 19 2017
U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD Jan 19 2017
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Jan 17 2017
FTSE 100 continues record run, rising for 14th day in a row Jan 13 2017
KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market... Jan 12 2017
Lawsuit accuses Shire of monopolizing market for ADHD drug Jan 12 2017
PRESS DIGEST- Financial Times - Jan 12 Jan 11 2017
[$$] Shire to Pay $350 Million to Settle Dermagraft Kickback Allegations Jan 11 2017
Pharmaceutical company agrees to ‘landmark’ settlement in Tampa federal court Jan 11 2017
Trump slams drug industry at press conference, sending biotech stocks tumbling Jan 11 2017
FTSE 100 logs 10th day of all-time highs Jan 11 2017
Shire CEO: Our innovation score is very high Jan 10 2017
Martin Whitman Invests in Homebuilder in 4th Quarter Jan 09 2017
Merrimack Pharma to Sell Cancer Drugs for $1B Jan 09 2017
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Jan 06 2017
For Shire PLC (ADR) (SHPG) Securing Hemophilia Market With Long Acting Version Is Crucial Jan 06 2017
Director Declaration Jan 06 2017
Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)